INPP5D (SHIP1) Inhibition to Shift Microglial Polarization

Target: INPP5D Composite Score: 0.458 Price: $0.46 Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.458

Top 59% of 649 hypotheses

T4 Speculative

Novel AI-generated, no external validation

Needs 1+ supporting citation to reach Provisional

C Mech. Plausibility 15% 0.42 Top 88%

D Evidence Strength 15% 0.38 Top 89%

B+ Novelty 12% 0.72 Top 64%

F Feasibility 12% 0.22 Top 94%

C Impact 12% 0.48 Top 93%

D Druggability 10% 0.32 Top 84%

D Safety Profile 8% 0.32 Top 90%

C+ Competition 6% 0.55 Top 79%

D Data Availability 5% 0.35 Top 93%

D Reproducibility 5% 0.38 Top 88%

Evidence

3 supporting | 6 opposing

Citation quality: 0%

Debates

1 session B+

Avg quality: 0.72

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

TREM2 agonism vs antagonism in DAM microglia

The disease-associated microglia (DAM) phenotype involves TREM2 upregulation, but whether therapeutic agonism or antagonism of TREM2 is beneficial remains contested across disease stages.

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.636 | Target: PLCG2

TREM2-APOE Axis Dissociation for Selective DAM Activation

Score: 0.590 | Target: TREM2-APOE axis

TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection

Score: 0.544 | Target: TYROBP

CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion

Score: 0.528 | Target: CSF1R-TREM2

TREM2-mTOR Co-Agonism for Metabolic Reprogramming

Score: 0.511 | Target: TREM2-mTOR pathway

CX3CR1-TREM2 Integration for Synapse Pruning Normalization

Score: 0.476 | Target: CX3CR1-TREM2

→ View full analysis & all 7 hypotheses

Description

Selective INPP5D inhibition to amplify pro-survival PI3K signaling in the presence of TREM2 agonism, enabling stronger DAM commitment under stress conditions

Figures & Visualizations

debate_overview for SDA-2026-04-01-gap-001 debate overview

pathway_diagram for SDA-2026-04-01-gap-001 pathway diagram

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 0 with PMID Validation: 0% 3 supporting / 6 opposing

✓ For (3)

No supporting evidence

No opposing evidence

(6) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 7CLIN 1GENE 1EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Enrichment: 'Phosphatidylinositol metabolic p…	Supporting	MECH	-	-	-	-	-	-
INPP5D genetically associated with AD through micr…	Supporting	GENE	-	-	-	-	-	-
Modulates PI3K/AKT pathway downstream of multiple …	Supporting	MECH	-	-	-	-	-	-
INPP5D haploinsufficiency has not been validated a…	Opposing	MECH	-	-	-	-	-	-
Emtricitabine (SHELL trial) was developed for ALS …	Opposing	MECH	-	-	-	-	-	-
The SHELL trial failed suggesting INPP5D inhibitio…	Opposing	MECH	-	-	-	-	-	-
PI3K/AKT signaling is tightly regulated; enhancing…	Opposing	CLIN	-	-	-	-	-	-
INPP5D sits downstream of multiple myeloid recepto…	Opposing	MECH	-	-	-	-	-	-
Limited direct evidence that INPP5D inhibition wou…	Opposing	MECH	-	-	-	-	-	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 3

Enrichment: 'Phosphatidylinositol metabolic process' (CSF1R, INPP5D, PLCG2; p=3.5e-06, odds ratio 142.4)

INPP5D genetically associated with AD through microglial signaling networks

Modulates PI3K/AKT pathway downstream of multiple myeloid receptors

✗ Opposing Evidence 6

INPP5D haploinsufficiency has not been validated as protective in AD models

Emtricitabine (SHELL trial) was developed for ALS and was terminated; extrapolation to AD is speculative

The SHELL trial failed suggesting INPP5D inhibition may not be viable

PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that…▼

PI3K/AKT signaling is tightly regulated; enhancing this pathway could promote microglial survival in ways that perpetuate neuroinflammation

INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling f…▼

INPP5D sits downstream of multiple myeloid receptors; global inhibition could amplify inflammatory signaling from TLRs and other receptors in harmful ways

Limited direct evidence that INPP5D inhibition would amplify TREM2-specific signals in microglia

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

[Dry run - no API key]

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

[Dry run - no API key]

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

[Dry run - no API key]

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

[Dry run - no API key]

Price History

7d Trend

↔

Stable

7d Momentum

▲ 0.0%

Volatility

Low

0.0000

Events (7d)

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (0)

No linked papers yet

📓 Linked Notebooks (5)

📓 Top 5 Analysis: Sda 2026 04 01 Gap 001

Computational notebook for SDA-2026-04-01-gap-001

📓 SciDEX Analysis: 2026 04 01 Gap 001

Computational notebook for SDA-2026-04-01-gap-001

📓 TREM2 agonism vs antagonism in DAM microglia - Rich Analysis

TREM2/DAM analysis with expression plots, pathway enrichment, hypothesis scoring

📓 TREM2 agonism vs antagonism in DAM microglia

Analysis ID: SDA-2026-04-01-gap-001

📓 TREM2 agonism vs antagonism in DAM microglia

Analysis ID: SDA-2026-04-01-gap-001 Date: 2026-04-01 Domain: neurodegeneration Key Hypotheses: - TREM2-Dependent Microglial Senescence Transition (score: 0.705) - Cell-Type Specific TREM …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

KG Entities (22)

APOE CSF1R CSF1R-TREM2 CX3CR1 CX3CR1-TREM2 DAM DAP12 INPP5D PLCG2 SHIP1 TREM2 TREM2-APOE axis TREM2-mTOR pathway TYROBP h-0cbe9bac h-0f025d94 h-2e03f316 h-39148342 h-5b378bd3 h-7597968b

Related Hypotheses

TREM2-Dependent Microglial Senescence Transition

Score: 0.736 | neurodegeneration

SASP-Mediated Complement Cascade Amplification

Score: 0.734 | neurodegeneration

LRP1-Dependent Tau Uptake Disruption

Score: 0.716 | neurodegeneration

Nutrient-Sensing Epigenetic Circuit Reactivation

Score: 0.700 | neurodegeneration

Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction

Score: 0.696 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (31 edges)

associated with (7)

PLCG2 → neurodegeneration

TREM2-APOE axis → neurodegeneration

CSF1R-TREM2 → neurodegeneration

TYROBP → neurodegeneration

TREM2-mTOR pathway → neurodegeneration

...and 2 more

co associated with (11)

PLCG2 → TREM2

TREM2-APOE axis → TREM2

TREM2-APOE axis → APOE

TREM2-APOE axis → DAM

CSF1R-TREM2 → CSF1R

...and 6 more

implicated in (6)

PLCG2 → neurodegeneration

TREM2-APOE axis → neurodegeneration

CSF1R-TREM2 → neurodegeneration

TREM2-mTOR pathway → neurodegeneration

CX3CR1-TREM2 → neurodegeneration

...and 1 more

targets (7)

h-0f025d94 → PLCG2

h-5b378bd3 → TREM2-APOE axis

h-0cbe9bac → CSF1R-TREM2

h-f503b337 → TYROBP

h-2e03f316 → TREM2-mTOR pathway

...and 2 more

Mechanism Pathway for INPP5D

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    h_39148342["h-39148342"] -->|targets| INPP5D["INPP5D"]
    INPP5D_1["INPP5D"] -->|associated with| neurodegeneration["neurodegeneration"]
    INPP5D_2["INPP5D"] -->|implicated in| neurodegeneration_3["neurodegeneration"]
    INPP5D_4["INPP5D"] -->|co associated with| SHIP1["SHIP1"]
    style h_39148342 fill:#4fc3f7,stroke:#333,color:#000
    style INPP5D fill:#ce93d8,stroke:#333,color:#000
    style INPP5D_1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style INPP5D_2 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_3 fill:#ef5350,stroke:#333,color:#000
    style INPP5D_4 fill:#ce93d8,stroke:#333,color:#000
    style SHIP1 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 INPP5D — PDB 2YSQ Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

TREM2 agonism vs antagonism in DAM microglia

neurodegeneration | 2026-04-01 | completed